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Background/Introduction
Acute kidney injury (AKI) is a significant complication
of cardiac surgery and is associated with increased mor-
bidity and mortality [1]. Despite much research, there is
no specific therapy available. Although AKI can be mul-
tifactorial, ischaemia reperfusion injury (IRI) often plays
a key role. Thus, cardiac surgery offers an attractive
opportunity for translational AKI research given the pre-
dictive haemodynamic challenge to renal perfusion.
Hemeoxygenase-1 (HO-1) is a key inducible anti-
inflammatory enzyme that catalyses the breakdown of
the pro-oxidant protein heme ubiquitously found at
inflamed sites. The drug heme arginate has been in use
for over 20 years in the treatment of porphyria but also
upregulates HO-1 in peripheral blood mononuclear cells
(PBMCs) [2] and ameliorates calf muscle ischaemia [3].
In addition, treatment of mice with heme arginate prior
to renal IRI strongly upregulates renal HO-1 expression
and protects from AKI [4]. We therefore hypothesise
that HA may offer a prophylactic therapy for human
renal IRI via the upregulation of HO-1.
Aims/Objectives
The HACS Trial aims to determine whether heme argi-
nate will upregulate HO-1 in PBMCs in patients aged
60 or above who are scheduled for cardiac surgery, and
to verify its safety in this patient cohort.
Method
20 participants, who are scheduled for elective cardiac sur-
gery, will be randomised to receive 1 mg/kg or 3 mg/kg
heme arginate. The primary end point will be the differ-
ence in PBMC HO-1 protein from baseline at 24 hours.
Secondary end points include HO-1 gene expression,
safety and HO-1 genotype.
Results
Results are expected in July 2015. At the time of
abstract submission, 14 of 20 participants have been
recruited.
Discussion/Conclusion
Data from the HACS trial will inform a subsequent multi-
centre randomised controlled trial of heme arginate versus
placebo in the prevention of AKI in patients deemed to be
at higher risk of developing AKI post cardiac surgery
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